News
AZ, Daiichi Sankyo’s Enhertu scores approval in the UK
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu has scored a conditional marketing authorisation in the UK for certain breast cancer patients.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu has scored a conditional marketing authorisation in the UK for certain breast cancer patients.